{
  "ticker": "GILD",
  "content": "**Report Generated:** January 14, 2026  \n**Next Refresh:** April 15, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# Gilead Sciences (GILD) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nGilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The company has evolved from a biotechnology startup into a global pharmaceutical powerhouse, with operations across more than 35 countries worldwide.\n\nGilead's therapeutic areas of focus include HIV/AIDS, liver diseases, cancer and inflammation, and serious respiratory diseases. Gilead Sciences, Inc. primarily makes money by developing and selling patented, high-value pharmaceutical products, with the vast majority of its revenue-nearly 70% in the third quarter of 2025-coming from its dominant portfolio of HIV treatments. The company maintains its position as a leader in antiviral therapeutics while expanding into oncology and inflammation markets through strategic acquisitions and partnerships.\n\n## 2. Current Market Data\n\nThe current price of GILD is 122.60 USD — it has increased by 0.36% in the past 24 hours. Today Gilead Sciences, Inc. has the market capitalization of ‪150.25 B‬, it has increased by 2.00% over the last week. The all-time high Gilead Sciences stock closing price was 127.23 on November 19, 2025. The Gilead Sciences 52-week high stock price is 128.70, which is 6.3% above the current share price. The Gilead Sciences 52-week low stock price is 89.02, which is 26.5% below the current share price. As of today, Dividend Yield (TTM)% is 2.61%. The stock carries a P/E ratio of 18.76 and has shown strong momentum with a 37.54% one-year total return.\n\n## 3. Existing Products/Services\n\nGilead's product portfolio spans multiple therapeutic areas:\n\n**HIV/AIDS Products:**\n- The company's flagship drug, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), for HIV-1 infection has become the number-one prescribed regimen for both treatment-naïve and switch patients. Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum for GILD in the upcoming quarters.\n- Descovy (FTC 200 mg/TAF 25 mg) for pre-exposure prophylaxis (PrEP) is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States.\n- The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; includes Atripla, Complera/Eviplera, Emtriva, Sunlenca, Stribild, Truvada, Tybost and Yeztugo/Yeytuo.\n\n**Hepatitis/Liver Diseases:**\n- Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis; includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi/Lyvdelzi, Sovaldi, Viread and Vosevi.\n\n**Oncology Products:**\n- It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology.\n\n## 4. Planned Products/Services/Projects\n\n**HIV Pipeline - 2026 and Beyond:**\nAt the J.P. Morgan Healthcare Conference 2026, Gilead Sciences CEO Daniel O'Day announced that the company currently has seven HIV drugs in its development pipeline. Key upcoming launches include:\n\n- The company also expects to present data from two Phase III trials (NCT06630286 and NCT06630299) of a weekly oral combination of MSDs islatravir and Gilead's lenacapavir in H1 2026, with hopes that this would prepare the company for a 2027 launch.\n- Back in PrEP, Gilead is hoping for a 2028 launch of its once-yearly lenacapavir, if the regimen demonstrates success in clinical trials.\n\n**Recent Regulatory Successes:**\n- Data show that ≥99.9% of participants who received Yeztugo in the Phase 3 PURPOSE 1 and PURPOSE 2 trials remained HIV negative. \"This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic,\" said Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences.\n\n**Inflammation Portfolio:**\nSeveral data readouts are planned for 2026. \"Next year is going to be a very exciting year to help us build our foundation in inflammation,\" Wenjun emphasizes. The pipeline now includes 13 assets, ranging from preclinical compounds to those in Phase 2 clinical trials, as well one therapy approved for use in the U.S. for the liver condition known as primary biliary cholangitis or PBC.\n\n## 5. Growth Strategy\n\nWith multiple potential product launches in 2026, the strongest clinical pipeline in Gilead's history, and no major loss of exclusivity expected until 2036, we are well-positioned to drive positive impact for patients and continued growth of our business.\n\n**Key Strategic Elements:**\n- Gilead invest 23% of its total revenue on R&D to ensure the sustainability of the business in the long term. Those investments enable Gilead to increase their drugs pipeline throughout the funnel, which leads to more frequent blockbuster drug discoveries that are released into market.\n- We would like to add more therapies just like Livdelzi,\" Dickinson said, noting that the pharma is consistently searching for \"best-in-class therapies that serve patients.\" In particular, Gilead is looking to add \"late-stage derisked assets\" at a pace of \"every two to three years at a minimum.\"\n- Aside from liver diseases, Gilead is also actively scouting for potential deals in oncology, virology, immunology and cell therapy.\n\n## 6. Current and Potential Major Clients\n\nGilead's clients span various healthcare sectors globally:\n\n**Market Reach:**\n- Gilead maintains direct sales force of 1,850 representatives as of 2023, targeting physicians, hospitals, and specialty clinics across infectious diseases and oncology segments.\n- As of 2024, Gilead maintains a dedicated sales force of approximately 1,850 pharmaceutical sales representatives across the United States. These representatives target approximately 85,000 healthcare providers specializing in infectious diseases, oncology, and liver health.\n\n**Global Access Programs:**\n- Announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (\"Global Fund\") to accelerate access, subject to regulatory approvals, to twice-yearly lenacapavir for HIV PrEP for up to two million people in primarily low- and lower-middle-income countries over three years, at no profit to Gilead.\n\n## 7. Financial Data & Performance\n\n**Q3 2025 Financial Results:**\n- Total third quarter 2025 revenues increased 3% to $7.8 billion compared to the same period in 2024.\n- Product Sales Excluding Veklury Increased 4% Year-Over-Year to $7.1 billion Biktarvy Sales Increased 6% Year-Over-Year to $3.7 billion.\n- Non-GAAP diluted EPS of $2.47 in the third quarter 2025 compared to $2.02 in the same period in 2024.\n- As of September 30, 2025, Gilead had $9.4 billion of cash, cash equivalents and marketable debt securities compared to $10.0 billion as of December 31, 2024. During the third quarter 2025, Gilead generated $4.1 billion in operating cash flow.\n\n**2025 Full-Year Guidance:**\n- The company is on track for a strong 2025, having raised its full-year product sales guidance to a range of $28.4 billion to $28.7 billion.\n- The full-year 2025 Non-GAAP diluted earnings per share (EPS) guidance was raised to a range of $8.05 to $8.25.\n\n## 8. Market Shares\n\n**HIV Market Dominance:**\n- HIV drug sales accounted for 69% of total product sales in the first quarter of 2025.\n- HIV products generated $19.6 billion for Gilead last year. Biktarvy, a once-daily pill for treating HIV, is the cornerstone of the portfolio, generating $13.4 billion in 2024.\n- The HIV market across the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan) is forecast to grow at a compound annual growth rate (CAGR) of 1.9% from $26.5bn in 2023 to $32.1bn in 2033.\n\n**Yeztugo Growth Prospects:**\n- The analyst consensus is that Yeztugo will achieve peak sales of around $4.5 billion.\n- The PrEP also has 85% payer coverage in the US, with it being available with a $0 copay on some policies.\n\n## 9. Comparison to Competitors\n\nGilead's main competitors include ViiV Healthcare, Roche, Bristol Myers Squibb, and Merck. Key competitive dynamics include:\n\n**Market Position:**\n- ViiV Healthcare: Focuses on long-acting injectables and different treatment regimens for HIV. Roche: Has a broad range of cancer therapies, including immunotherapies and targeted therapies. Bristol Myers Squibb: Competes in cell therapy with products like Abecma and Breyanzi. Merck & Co.: Competes in the antiviral space with its own pipeline and products.\n\n**Competitive Advantages:**\n- While the HIV market remains fiercely competitive—with new entrants such as long-acting injectables vying for attention—Gilead's brand recognition, strong clinical data, and patient loyalty afford it a competitive advantage.\n- On top of new launches, Gilead still has some protection of its marketed therapies, with its flagship HIV ART, Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide), not losing exclusivity until 2036.\n\n## 10. Partnerships, Mergers and Acquisitions\n\n**Recent Acquisitions (2025-2026):**\n- In February 2024, the company acquired CymaBay Therapeutics, and in September, paid Genesis Therapeutics $35 million for AI-based drug discovery work.\n- Gilead Sciences is deepening its investment in cancer cell therapy, announcing Thursday a deal to pay $350 million to buy privately held Interius BioTherapeutics for a technology designed to reprogram immune cells in patients' bodies.\n\n**Strategic Partnerships:**\n- Gilead Sciences, Inc. and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma's small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases.\n- The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc.\n\n**Recent Licensing Deals:**\n- Meanwhile, Gilead is offering a more modest $25 million upfront payment for the rights to Repare Therapeutics' polymerase theta (Polθ) ATPase inhibitor, dubbed RP-3467.\n\n## 11. Recent Developments\n\n**2025 Key Regulatory Milestones:**\n- Data show that ≥99.9% of participants who received Yeztugo in the Phase 3 PURPOSE 1 and PURPOSE 2 trials remained HIV negative. \"This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic,\" said Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences.\n\n**Clinical Pipeline Progress:**\n- Gilead announced on December 15, 2025 that its investigational single‑tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) met the Phase 3 ARTISTRY‑2 primary endpoint, demonstrating statistical non‑inferiority to BIKTARVY by the FDA snapshot at Week 48. The regimen was generally well tolerated with no new safety signals reported.\n\n**Manufacturing Investment:**\n- Announced ground-breaking on a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City, California as part of a planned $32 billion investment in the U.S. through 2030.\n\n**Global Access Initiatives:**\n- Announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (\"Global Fund\") to accelerate access, subject to regulatory approvals, to twice-yearly lenacapavir for HIV PrEP for up to two million people in primarily low- and lower-middle-income countries over three years, at no profit to Gilead.\n\n## 12. AI Investment Rating & Fair Value Assessment\n\n**Investment Strengths:**\n- Dominant market position in HIV with 70% of revenue protected until 2036\n- Strong cash generation ($4.1 billion operating cash flow in Q3 2025)\n- Revolutionary Yeztugo launch with $4.5 billion peak sales potential\n- Robust pipeline with seven HIV drugs in development\n- Multiple 2026 product launches anticipated\n\n**Key Risks:**\n- Heavy dependence on HIV franchise creates concentration risk\n- Competitive pressures in oncology and cell therapy markets\n- Regulatory uncertainties with pipeline products\n- Potential pricing pressures from Medicare reforms\n\n**Analyst Sentiment:**\nBased on the one-year price targets offered by 27 analysts, the average target price for Gilead Sciences Inc is $134.45 with a high estimate of $154.00 and a low estimate of $100.00. The average target implies an upside of 9.25% from the current price of $123.07.\n\n**Buy Rating: 7.8/10**\n\nBased on the comprehensive analysis, Gilead Sciences merits a buy rating of 7.8/10. The company demonstrates strong fundamentals with its dominant HIV franchise, revolutionary Yeztugo launch, and robust pipeline. The recent Q3 2025 earnings beat, strong cash generation, and patent protection until 2036 provide a solid foundation. However, the concentration risk in HIV, competitive pressures in oncology, and execution risks with pipeline products prevent a higher rating.\n\n**Fair Value Estimate: $138-142 per share**\n\nThe fair value range reflects:\n- Premium valuation for HIV market dominance and Yeztugo's breakthrough potential\n- Multiple expansion justified by pipeline strength and 2026 launch slate\n- Modest discount to account for concentration risk and competitive pressures\n- Upside potential from successful pipeline execution and market share gains in emerging therapeutic areas\n\nThis target represents approximately 13-16% upside from current levels, making GILD an attractive investment for growth-oriented portfolios with moderate risk tolerance.",
  "generated_date": "2026-01-14T07:15:50.810031",
  "next_refresh_date": "2026-04-15T07:15:50.810031",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.43220925000000004,
  "tokens": {
    "input": 190,
    "output": 5322,
    "cache_creation": 74635,
    "cache_read": 239760
  },
  "tldr_summary": "Gilead Sciences is a biopharmaceutical company specializing in developing antiviral drugs, with a primary focus on HIV/AIDS treatments and expanding into oncology and inflammation markets. \n\nThe company dominates the HIV treatment market with Biktarvy, which accounts for over 51% market share, and is preparing to launch revolutionary products like Yeztugo, a breakthrough HIV prevention drug with potential peak sales of $4.5 billion. Gilead's strategic approach involves investing 23% of revenue in R&D, pursuing strategic acquisitions, and expanding into new therapeutic areas. The company has a robust pipeline with seven HIV drugs in development and strong patent protection until 2036, positioning it well for future growth. Key competitive advantages include brand recognition, clinical data strength, and a diverse portfolio spanning HIV, hepatitis, oncology, and emerging inflammation treatments.\n\nWith a buy rating of 7.8/10 and a fair value estimate of $138-142 per share, Gilead represents an attractive investment opportunity with approximately 13-16% upside potential."
}